Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Traffic & App Usage Insights

Discover domain traffic and app usage trends for companies and their competitors.

Last Close
Oct 31 04:00PM ET
0.9957
Dollar change
+0.0037
Percentage change
0.37
%
Index- P/E7.15 EPS (ttm)0.14 Insider Own1.69% Shs Outstand78.12M Perf Week-7.81%
Market Cap77.78M Forward P/E- EPS next Y-0.61 Insider Trans-2.11% Shs Float76.79M Perf Month-13.42%
Income11.09M PEG- EPS next Q-0.17 Inst Own72.89% Short Float7.90% Perf Quarter-23.99%
Sales119.57M P/S0.65 EPS this Y-3053.00% Inst Trans32.56% Short Ratio8.93 Perf Half Y-77.87%
Book/sh-0.40 P/B- EPS next Y-94.48% ROA6.02% Short Interest6.07M Perf Year-9.48%
Cash/sh1.76 P/C0.57 EPS next 5Y-0.90% ROE- 52W Range0.99 - 5.85 Perf YTD-35.76%
Dividend Est.- P/FCF- EPS past 5Y67.21% ROI- 52W High-82.98% Beta1.05
Dividend TTM- Quick Ratio1.00 Sales past 5Y28.25% Gross Margin97.63% 52W Low0.76% ATR (14)0.05
Dividend Ex-Date- Current Ratio1.00 EPS Y/Y TTM125.46% Oper. Margin11.45% RSI (14)32.47 Volatility5.48% 4.57%
Employees122 Debt/Eq- Sales Y/Y TTM40.24% Profit Margin9.27% Recom2.00 Target Price5.31
Option/ShortYes / Yes LT Debt/Eq- EPS Q/Q-372.39% Payout- Rel Volume0.58 Prev Close0.99
Sales Surprise25.57% EPS Surprise19.84% Sales Q/Q1.58% EarningsAug 08 AMC Avg Volume679.03K Price1.00
SMA20-9.71% SMA50-14.04% SMA200-39.07% Trades Volume395,432 Change0.37%
Date Action Analyst Rating Change Price Target Change
May-28-24Upgrade Piper Sandler Neutral → Overweight $2.25 → $3.50
May-09-24Upgrade Wedbush Neutral → Outperform $8
May-06-24Upgrade Jefferies Hold → Buy $2.50 → $8
Apr-22-24Upgrade JP Morgan Underweight → Neutral
Nov-14-22Downgrade BMO Capital Markets Outperform → Market Perform $3 → $2.60
Jul-07-22Downgrade Wedbush Outperform → Neutral $6 → $2
Jul-07-22Downgrade Piper Sandler Overweight → Neutral $10 → $1.50
Jul-07-22Downgrade Mizuho Buy → Neutral $16 → $4
Jul-07-22Downgrade Jefferies Buy → Hold $12 → $2
Jun-24-22Initiated BMO Capital Markets Outperform $9
Today 08:00AM
Sep-09-24 08:00AM
Sep-04-24 08:00AM
Aug-10-24 08:18AM
Aug-08-24 09:56PM
05:46PM Loading…
05:46PM
04:10PM
Aug-01-24 08:00AM
Jul-25-24 02:26AM
Jun-18-24 08:00AM
Jun-17-24 04:15PM
Jun-05-24 06:00AM
Jun-03-24 09:17AM
May-29-24 06:25AM
May-22-24 04:05PM
04:15PM Loading…
May-16-24 04:15PM
May-15-24 11:14AM
May-09-24 04:17PM
11:56AM
11:32AM
08:12AM
07:48AM
07:29AM
04:01AM
May-08-24 09:58PM
04:30PM
04:10PM
04:10PM
May-07-24 04:15PM
May-06-24 07:09AM
08:08AM Loading…
May-02-24 08:08AM
07:37AM
May-01-24 12:11PM
11:43AM
08:00AM
Apr-08-24 08:00AM
Apr-03-24 08:00AM
Mar-21-24 08:00AM
Mar-18-24 08:00AM
Mar-12-24 09:12AM
08:30AM
06:46AM
Mar-11-24 05:34PM
05:20PM
04:10PM
Mar-04-24 08:00AM
Feb-27-24 11:52AM
08:00AM
Jan-24-24 08:00AM
Jan-12-24 08:00AM
Jan-04-24 08:00AM
Dec-21-23 08:00AM
Nov-13-23 12:00PM
Nov-08-23 10:15AM
Nov-07-23 05:05PM
04:15PM
Nov-01-23 08:00AM
Oct-31-23 08:00AM
Oct-30-23 08:00AM
Oct-18-23 04:30PM
Sep-05-23 04:05PM
Aug-25-23 09:35AM
Aug-10-23 04:05PM
Aug-08-23 05:30PM
04:26PM
04:15PM
Aug-01-23 08:00AM
Jul-20-23 09:00AM
Jul-17-23 08:00AM
Jun-30-23 08:00AM
Jun-08-23 09:02AM
Jun-01-23 04:05PM
May-11-23 06:05AM
May-10-23 08:13AM
May-09-23 05:35PM
04:26PM
04:15PM
May-05-23 06:34AM
May-01-23 04:01PM
10:01AM
Apr-27-23 10:03AM
Apr-25-23 04:05PM
Mar-30-23 11:26AM
Mar-29-23 06:06AM
Mar-28-23 01:35PM
Mar-27-23 05:35PM
04:15PM
Mar-22-23 07:23PM
Mar-20-23 06:14AM
Feb-28-23 04:05PM
Feb-07-23 06:07AM
Jan-26-23 07:00AM
Jan-17-23 04:05PM
Jan-12-23 05:30AM
Jan-06-23 06:44PM
01:46PM
10:30AM
Jan-05-23 05:11PM
04:19PM
04:05PM
CytomX Therapeutics, Inc. is a clinical-stage, oncology-focused biopharmaceutical company, which engages in the development of conditionally activated, biologics localized to the tumor microenvironment. The company was founded by Frederick W. Gluck and Nancy E. Stagliano in September 2010 and is headquartered in South San Francisco, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Landau Jeffrey BChief Business OfficerAug 20 '24Option Exercise0.0011,2500123,237Aug 22 06:01 PM
Landau Jeffrey BChief Business OfficerAug 20 '24Sale1.234,1815,139119,056Aug 22 06:01 PM
BELVIN MARCIASVP, Chief Scientific OfficerAug 20 '24Option Exercise0.0011,2500179,829Aug 22 06:01 PM
BELVIN MARCIASVP, Chief Scientific OfficerAug 20 '24Sale1.234,1815,139175,648Aug 22 06:01 PM
ROWLAND LLOYD AGeneral CounselAug 20 '24Option Exercise0.0011,2500134,978Aug 22 06:00 PM
ROWLAND LLOYD AGeneral CounselAug 20 '24Sale1.234,1815,139130,797Aug 22 06:00 PM
Ogden ChristopherChief Financial OfficerAug 20 '24Option Exercise0.006,8750110,061Aug 22 05:59 PM
Ogden ChristopherChief Financial OfficerAug 20 '24Sale1.231,9842,439108,077Aug 22 05:59 PM
McCarthy Sean A.CEOAug 20 '24Option Exercise0.0037,5000671,749Aug 22 05:58 PM
McCarthy Sean A.CEOAug 20 '24Sale1.2313,89817,082657,851Aug 22 05:58 PM
McCarthy Sean A.CEOMar 26 '24Option Exercise1.57109,768172,874634,249Mar 28 07:12 PM
ROWLAND LLOYD AGeneral CounselMar 19 '24Sale2.095,26810,986117,728Mar 21 04:41 PM
McCarthy Sean A.CEOMar 19 '24Sale2.0920,22342,175524,481Mar 21 04:40 PM
Ogden ChristopherSVP, Finance and AccountingMar 19 '24Sale2.092,9716,19685,686Mar 21 04:38 PM
BELVIN MARCIASVP, Chief Scientific OfficerMar 19 '24Sale2.0912,79526,684168,579Mar 21 04:37 PM
Landau Jeffrey BChief Business OfficerMar 19 '24Sale2.096,56213,685110,060Mar 21 04:36 PM
McCarthy Sean A.CEODec 20 '23Sale1.3813,55118,710454,704Dec 22 04:16 PM
BELVIN MARCIASVP, Chief Scientific OfficerDec 20 '23Sale1.384,0775,628155,124Dec 22 04:14 PM
Landau Jeffrey BChief Business OfficerDec 20 '23Sale1.384,0775,62886,622Dec 22 04:12 PM
ROWLAND LLOYD AGeneral CounselDec 20 '23Sale1.384,0775,62997,996Dec 22 04:11 PM
Ogden ChristopherSVP, Finance and AccountingDec 20 '23Sale1.381,9902,74748,657Dec 22 04:10 PM
Ogden ChristopherSVP, Finance and AccountingDec 17 '23Option Exercise0.006,875050,647Dec 19 07:58 PM
McCarthy Sean A.CEODec 17 '23Option Exercise0.0037,5000468,255Dec 19 07:57 PM
Landau Jeffrey BChief Business OfficerDec 17 '23Option Exercise0.0011,250090,699Dec 19 07:56 PM
ROWLAND LLOYD AGeneral CounselDec 17 '23Option Exercise0.0011,2500102,073Dec 19 07:55 PM
BELVIN MARCIASVP, Chief Scientific OfficerDec 17 '23Option Exercise0.0011,2500159,201Dec 19 07:54 PM